{"id":121876,"date":"2022-09-02T11:41:12","date_gmt":"2022-09-02T11:41:12","guid":{"rendered":"https:\/\/raed.academy\/?p=121876"},"modified":"2022-09-16T10:15:49","modified_gmt":"2022-09-16T10:15:49","slug":"la-lluita-contra-el-cancer-colonorrectal","status":"publish","type":"post","link":"https:\/\/raed.academy\/ca\/la-lluita-contra-el-cancer-colonorrectal\/","title":{"rendered":"La lluita contra el c\u00e0ncer colonorrectal"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-122083\" src=\"https:\/\/raed.academy\/wp-content\/uploads\/2022\/09\/cancer-colorrectal-dst.jpeg\" alt=\"\" width=\"451\" height=\"212\" \/><a href=\"https:\/\/raed.academy\/ca\/academics\/dr-francisco-lopez-munoz\/\" target=\"_blank\" rel=\"noopener\"><em><strong>Francisco L\u00f3pez Mu\u00f1oz<\/strong><\/em><\/a>, professor de Farmacologia i vicerector de Recerca, Ci\u00e8ncia i Doctorat de la <strong>Universitat Camilo Jos\u00e9 Cela<\/strong> i acad\u00e8mic de n\u00famero de la <strong>Reial Acad\u00e8mia Europea de Doctors-Barcelona 1914<\/strong> (RAED), reflexiona sobre els aven\u00e7os de la farmacologia en la lluita contra el c\u00e0ncer a l&#8217;article <strong>&#8220;Dostarlimab: \u00bfse est\u00e1 ganando la batalla al c\u00e1ncer colorrectal?&#8221;<\/strong>, publicat al portal de divulgaci\u00f3 cient\u00edfica <strong>The Conversation<\/strong> el 27 de juliol passat. <strong>L\u00f3pez Mu\u00f1oz<\/strong> signa el treball amb<strong> Jos\u00e9 Antonio Guerra Guirao<\/strong>, professor de Farmacologia i Toxicologia de la <strong>Universitat Complutense de Madrid<\/strong>. Ambd\u00f3s experts apel\u00b7len a un optimisme contingut respecte al resultat en el tractament del c\u00e0ncer de c\u00f2lon d&#8217;un f\u00e0rmac encara en assaig publicat recentment a la revista <strong>&#8220;The New England Journal of Medicine&#8221;<\/strong>.<\/p>\n<p>&#8220;El dostarlimab tamb\u00e9 est\u00e0 sent avaluat en assaigs cl\u00ednics de fase II en pacients amb c\u00e0ncer colonorrectal dMMR. Han estat publicats els resultats de l&#8217;assaig NCT04165772, en qu\u00e8 es van administrar 500 mg, cada 3 setmanes i durant 6 mesos, a persones en estadi II o III Els criteris principals de valoraci\u00f3 van ser la resposta cl\u00ednica completa (abs\u00e8ncia d&#8217;evid\u00e8ncia del tumor a l&#8217;examen cl\u00ednic, endosc\u00f2pic o per imatge) en 12 mesos despr\u00e9s de concloure el tractament amb dostarlimab o la resposta patol\u00f2gica completa (abs\u00e8ncia de lesi\u00f3 tumoral despr\u00e9s d&#8217;analitzar el teixit sota el microscopi) despr\u00e9s de la finalitzaci\u00f3 d&#8217;aquest tractament, amb quimiorradioter\u00e0pia o sense. Aix\u00ed i tot, la mostra d&#8217;aquest estudi va ser molt petita: de tan sols 12 pacients&#8221;, expliquen <strong>L\u00f3pez Mu\u00f1oz<\/strong> i <strong>Guerra Guirao<\/strong> situant l&#8217;abast de les conclusions d&#8217;aquest estudi.<\/p>\n<div id=\"attachment_41638\" style=\"width: 439px\" class=\"wp-caption alignright\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-41638\" class=\"wp-image-41638\" src=\"https:\/\/raed.academy\/wp-content\/uploads\/2018\/02\/acto-ingreso-Francisco-Lopez-Mu\u00f1oz-14.jpg\" sizes=\"(max-width: 429px) 100vw, 429px\" srcset=\"https:\/\/raed.academy\/wp-content\/uploads\/2018\/02\/acto-ingreso-Francisco-Lopez-Mu\u00f1oz-14.jpg 800w, https:\/\/raed.academy\/wp-content\/uploads\/2018\/02\/acto-ingreso-Francisco-Lopez-Mu\u00f1oz-14-768x512.jpg 768w\" alt=\"Acto de ingreso de Francisco L\u00f3pez Mu\u00f1oz\" width=\"429\" height=\"286\" aria-describedby=\"caption-attachment-41638\" \/><p id=\"caption-attachment-41638\" class=\"wp-caption-text\">Dr. Francisco L\u00f3pez Mu\u00f1oz<\/p><\/div>\n<p>Per als experts, els resultats publicats per &#8220;The New England Journal of Medicine&#8221; poden semblar espectaculars i \u00e9s una evid\u00e8ncia que el f\u00e0rmac obre una nova forma d&#8217;abordar el tractament dels malalts amb aquest tipus de patologia, per si mateix molt heterog\u00e8nia. No obstant aix\u00f2, la mida redu\u00efda de la mostra analitzada \u00e9s una limitaci\u00f3 molt important i es requereix la seva confirmaci\u00f3 en una s\u00e8rie major de pacients. Per tant, apel\u00b7len que es confirmin aquestes dades inicials en una mostra de pacients molt m\u00e9s gran i fer-ne un seguiment m\u00e9s llarg. I, sobretot, a comparar els resultats amb els tractaments convencionals: radioter\u00e0pia, quimioter\u00e0pia i cirurgia.<\/p>\n<p>El c\u00e0ncer colorectal \u00e9s el tercer tipus de tumor m\u00e9s prevalent i el segon en termes de mortalitat a tot el m\u00f3n. A Espanya, la incid\u00e8ncia estimada \u00e9s de 43.398 casos: 28.706 tumors de c\u00f2lon i 14.664 de recte el 2022. Al voltant del 25% dels pacients presenten malaltia metast\u00e0tica en el moment del diagn\u00f2stic, i un ter\u00e7 de les persones amb malaltia limitada inicialment desenvoluparan met\u00e0stasi amb posterioritat. Aix\u00f2 explica les altes taxes de mortalitat notificades per als tumors colorectals. <strong>L\u00f3pez Mu\u00f1oz<\/strong> i <strong>Guerra Guirao<\/strong> assenyalen la variabilitat important d&#8217;aquesta malaltia. Un dels subgrups gen\u00e8tics ben descrits s\u00f3n els tumors amb defici\u00e8ncia del sistema de reparaci\u00f3 d&#8217;aparellaments erronis o alta inestabilitat de microsat\u00e8l\u00b7lits (dMMR o MSI-H, per les sigles en angl\u00e8s, respectivament). Suposen el 15% de tots els pacients i el 4% dels malalts amb c\u00e0ncer colonorrectal mestast\u00e0sic.<\/p>\n<h2><a href=\"https:\/\/theconversation.com\/dostarlimab-se-esta-ganando-la-batalla-al-cancer-colorrectal-187718\" target=\"_blank\" rel=\"noopener\">Llegiu l&#8217;article<\/a><\/h2>\n","protected":false},"excerpt":{"rendered":"<p>Els aven\u00e7os de la farmacologia en la lluita contra el c\u00e0ncer a l&#8217;article &#8220;Dostarlimab: \u00bfse est\u00e1 ganando la batalla al c\u00e1ncer colorrectal?&#8221;, per Francisco L\u00f3pez Mu\u00f1oz<\/p>\n","protected":false},"author":12,"featured_media":122084,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[455,442],"tags":[],"class_list":["post-121876","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ciencies-de-la-salut","category-ciencies-farmaceutiques-ciencies-de-la-salut","et-has-post-format-content","et_post_format-et-post-format-standard"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>La lluita contra el c\u00e0ncer colonorrectal - Reial Acad\u00e8mia Europea de Doctors<\/title>\n<meta name=\"description\" content=\"Els aven\u00e7os de la farmacologia a l&#039;article &quot;Dostarlimab: \u00bfse est\u00e1 ganando la batalla al c\u00e1ncer colorrectal?&quot;, per Francisco L\u00f3pez Mu\u00f1oz\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/raed.academy\/ca\/la-lluita-contra-el-cancer-colonorrectal\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La lluita contra el c\u00e0ncer colonorrectal - Reial Acad\u00e8mia Europea de Doctors\" \/>\n<meta property=\"og:description\" content=\"Els aven\u00e7os de la farmacologia a l&#039;article &quot;Dostarlimab: \u00bfse est\u00e1 ganando la batalla al c\u00e1ncer colorrectal?&quot;, per Francisco L\u00f3pez Mu\u00f1oz\" \/>\n<meta property=\"og:url\" content=\"https:\/\/raed.academy\/ca\/la-lluita-contra-el-cancer-colonorrectal\/\" \/>\n<meta property=\"og:site_name\" content=\"Reial Acad\u00e8mia Europea de Doctors\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/fb.me\/raed.academy\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-02T11:41:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-16T10:15:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/raed.academy\/wp-content\/uploads\/2022\/09\/cancer-colorrectal-dst.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"282\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"RAED\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@raedacademy\" \/>\n<meta name=\"twitter:site\" content=\"@raedacademy\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"RAED\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/raed.academy\\\/ca\\\/la-lluita-contra-el-cancer-colonorrectal\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/raed.academy\\\/ca\\\/la-lluita-contra-el-cancer-colonorrectal\\\/\"},\"author\":{\"name\":\"RAED\",\"@id\":\"https:\\\/\\\/raed.academy\\\/ca\\\/#\\\/schema\\\/person\\\/5a755da80d1d979fd66ba745c8702927\"},\"headline\":\"La lluita contra el c\u00e0ncer colonorrectal\",\"datePublished\":\"2022-09-02T11:41:12+00:00\",\"dateModified\":\"2022-09-16T10:15:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/raed.academy\\\/ca\\\/la-lluita-contra-el-cancer-colonorrectal\\\/\"},\"wordCount\":584,\"publisher\":{\"@id\":\"https:\\\/\\\/raed.academy\\\/ca\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/raed.academy\\\/ca\\\/la-lluita-contra-el-cancer-colonorrectal\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/raed.academy\\\/wp-content\\\/uploads\\\/2022\\\/09\\\/cancer-colorrectal-dst.jpeg\",\"articleSection\":[\"Ci\u00e8ncies de la salut\",\"Ci\u00e8ncies Farmac\u00e8utiques\"],\"inLanguage\":\"ca-ES\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/raed.academy\\\/ca\\\/la-lluita-contra-el-cancer-colonorrectal\\\/\",\"url\":\"https:\\\/\\\/raed.academy\\\/ca\\\/la-lluita-contra-el-cancer-colonorrectal\\\/\",\"name\":\"La lluita contra el c\u00e0ncer colonorrectal - Reial Acad\u00e8mia Europea de Doctors\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/raed.academy\\\/ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/raed.academy\\\/ca\\\/la-lluita-contra-el-cancer-colonorrectal\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/raed.academy\\\/ca\\\/la-lluita-contra-el-cancer-colonorrectal\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/raed.academy\\\/wp-content\\\/uploads\\\/2022\\\/09\\\/cancer-colorrectal-dst.jpeg\",\"datePublished\":\"2022-09-02T11:41:12+00:00\",\"dateModified\":\"2022-09-16T10:15:49+00:00\",\"description\":\"Els aven\u00e7os de la farmacologia a l'article \\\"Dostarlimab: \u00bfse est\u00e1 ganando la batalla al c\u00e1ncer colorrectal?\\\", per Francisco L\u00f3pez Mu\u00f1oz\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/raed.academy\\\/ca\\\/la-lluita-contra-el-cancer-colonorrectal\\\/#breadcrumb\"},\"inLanguage\":\"ca-ES\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/raed.academy\\\/ca\\\/la-lluita-contra-el-cancer-colonorrectal\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca-ES\",\"@id\":\"https:\\\/\\\/raed.academy\\\/ca\\\/la-lluita-contra-el-cancer-colonorrectal\\\/#primaryimage\",\"url\":\"https:\\\/\\\/raed.academy\\\/wp-content\\\/uploads\\\/2022\\\/09\\\/cancer-colorrectal-dst.jpeg\",\"contentUrl\":\"https:\\\/\\\/raed.academy\\\/wp-content\\\/uploads\\\/2022\\\/09\\\/cancer-colorrectal-dst.jpeg\",\"width\":600,\"height\":282},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/raed.academy\\\/ca\\\/la-lluita-contra-el-cancer-colonorrectal\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/raed.academy\\\/ca\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La lluita contra el c\u00e0ncer colonorrectal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/raed.academy\\\/ca\\\/#website\",\"url\":\"https:\\\/\\\/raed.academy\\\/ca\\\/\",\"name\":\"Reial Acad\u00e8mia Europea de Doctors\",\"description\":\"Corporaci\u00f3n de derecho p\u00fablico de car\u00e1cter cient\u00edfico, t\u00e9cnico y art\u00edstico, que tiene por objeto la investigaci\u00f3n, el estudio, el fomento y la extensi\u00f3n del conocimiento en su sentido m\u00e1s amplio\",\"publisher\":{\"@id\":\"https:\\\/\\\/raed.academy\\\/ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/raed.academy\\\/ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca-ES\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/raed.academy\\\/ca\\\/#organization\",\"name\":\"Real Academia Europea de Doctores\",\"url\":\"https:\\\/\\\/raed.academy\\\/ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca-ES\",\"@id\":\"https:\\\/\\\/raed.academy\\\/ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/raed.academy\\\/wp-content\\\/uploads\\\/2017\\\/01\\\/cropped-logo_raed.png\",\"contentUrl\":\"https:\\\/\\\/raed.academy\\\/wp-content\\\/uploads\\\/2017\\\/01\\\/cropped-logo_raed.png\",\"width\":512,\"height\":512,\"caption\":\"Real Academia Europea de Doctores\"},\"image\":{\"@id\":\"https:\\\/\\\/raed.academy\\\/ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"http:\\\/\\\/fb.me\\\/raed.academy\",\"https:\\\/\\\/x.com\\\/raedacademy\",\"https:\\\/\\\/www.instagram.com\\\/raed.academy\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCUYQwW2KrdirNWihxMDObwg\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/raed.academy\\\/ca\\\/#\\\/schema\\\/person\\\/5a755da80d1d979fd66ba745c8702927\",\"name\":\"RAED\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca-ES\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/19fdfdc0d67fb9c45714b703a2ac82251c4fcea3637f002ac3c9b74c0183583c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/19fdfdc0d67fb9c45714b703a2ac82251c4fcea3637f002ac3c9b74c0183583c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/19fdfdc0d67fb9c45714b703a2ac82251c4fcea3637f002ac3c9b74c0183583c?s=96&d=mm&r=g\",\"caption\":\"RAED\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La lluita contra el c\u00e0ncer colonorrectal - Reial Acad\u00e8mia Europea de Doctors","description":"Els aven\u00e7os de la farmacologia a l'article \"Dostarlimab: \u00bfse est\u00e1 ganando la batalla al c\u00e1ncer colorrectal?\", per Francisco L\u00f3pez Mu\u00f1oz","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/raed.academy\/ca\/la-lluita-contra-el-cancer-colonorrectal\/","og_locale":"ca_ES","og_type":"article","og_title":"La lluita contra el c\u00e0ncer colonorrectal - Reial Acad\u00e8mia Europea de Doctors","og_description":"Els aven\u00e7os de la farmacologia a l'article \"Dostarlimab: \u00bfse est\u00e1 ganando la batalla al c\u00e1ncer colorrectal?\", per Francisco L\u00f3pez Mu\u00f1oz","og_url":"https:\/\/raed.academy\/ca\/la-lluita-contra-el-cancer-colonorrectal\/","og_site_name":"Reial Acad\u00e8mia Europea de Doctors","article_publisher":"http:\/\/fb.me\/raed.academy","article_published_time":"2022-09-02T11:41:12+00:00","article_modified_time":"2022-09-16T10:15:49+00:00","og_image":[{"width":600,"height":282,"url":"https:\/\/raed.academy\/wp-content\/uploads\/2022\/09\/cancer-colorrectal-dst.jpeg","type":"image\/jpeg"}],"author":"RAED","twitter_card":"summary_large_image","twitter_creator":"@raedacademy","twitter_site":"@raedacademy","twitter_misc":{"Written by":"RAED","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/raed.academy\/ca\/la-lluita-contra-el-cancer-colonorrectal\/#article","isPartOf":{"@id":"https:\/\/raed.academy\/ca\/la-lluita-contra-el-cancer-colonorrectal\/"},"author":{"name":"RAED","@id":"https:\/\/raed.academy\/ca\/#\/schema\/person\/5a755da80d1d979fd66ba745c8702927"},"headline":"La lluita contra el c\u00e0ncer colonorrectal","datePublished":"2022-09-02T11:41:12+00:00","dateModified":"2022-09-16T10:15:49+00:00","mainEntityOfPage":{"@id":"https:\/\/raed.academy\/ca\/la-lluita-contra-el-cancer-colonorrectal\/"},"wordCount":584,"publisher":{"@id":"https:\/\/raed.academy\/ca\/#organization"},"image":{"@id":"https:\/\/raed.academy\/ca\/la-lluita-contra-el-cancer-colonorrectal\/#primaryimage"},"thumbnailUrl":"https:\/\/raed.academy\/wp-content\/uploads\/2022\/09\/cancer-colorrectal-dst.jpeg","articleSection":["Ci\u00e8ncies de la salut","Ci\u00e8ncies Farmac\u00e8utiques"],"inLanguage":"ca-ES"},{"@type":"WebPage","@id":"https:\/\/raed.academy\/ca\/la-lluita-contra-el-cancer-colonorrectal\/","url":"https:\/\/raed.academy\/ca\/la-lluita-contra-el-cancer-colonorrectal\/","name":"La lluita contra el c\u00e0ncer colonorrectal - Reial Acad\u00e8mia Europea de Doctors","isPartOf":{"@id":"https:\/\/raed.academy\/ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/raed.academy\/ca\/la-lluita-contra-el-cancer-colonorrectal\/#primaryimage"},"image":{"@id":"https:\/\/raed.academy\/ca\/la-lluita-contra-el-cancer-colonorrectal\/#primaryimage"},"thumbnailUrl":"https:\/\/raed.academy\/wp-content\/uploads\/2022\/09\/cancer-colorrectal-dst.jpeg","datePublished":"2022-09-02T11:41:12+00:00","dateModified":"2022-09-16T10:15:49+00:00","description":"Els aven\u00e7os de la farmacologia a l'article \"Dostarlimab: \u00bfse est\u00e1 ganando la batalla al c\u00e1ncer colorrectal?\", per Francisco L\u00f3pez Mu\u00f1oz","breadcrumb":{"@id":"https:\/\/raed.academy\/ca\/la-lluita-contra-el-cancer-colonorrectal\/#breadcrumb"},"inLanguage":"ca-ES","potentialAction":[{"@type":"ReadAction","target":["https:\/\/raed.academy\/ca\/la-lluita-contra-el-cancer-colonorrectal\/"]}]},{"@type":"ImageObject","inLanguage":"ca-ES","@id":"https:\/\/raed.academy\/ca\/la-lluita-contra-el-cancer-colonorrectal\/#primaryimage","url":"https:\/\/raed.academy\/wp-content\/uploads\/2022\/09\/cancer-colorrectal-dst.jpeg","contentUrl":"https:\/\/raed.academy\/wp-content\/uploads\/2022\/09\/cancer-colorrectal-dst.jpeg","width":600,"height":282},{"@type":"BreadcrumbList","@id":"https:\/\/raed.academy\/ca\/la-lluita-contra-el-cancer-colonorrectal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/raed.academy\/ca\/"},{"@type":"ListItem","position":2,"name":"La lluita contra el c\u00e0ncer colonorrectal"}]},{"@type":"WebSite","@id":"https:\/\/raed.academy\/ca\/#website","url":"https:\/\/raed.academy\/ca\/","name":"Reial Acad\u00e8mia Europea de Doctors","description":"Corporaci\u00f3n de derecho p\u00fablico de car\u00e1cter cient\u00edfico, t\u00e9cnico y art\u00edstico, que tiene por objeto la investigaci\u00f3n, el estudio, el fomento y la extensi\u00f3n del conocimiento en su sentido m\u00e1s amplio","publisher":{"@id":"https:\/\/raed.academy\/ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/raed.academy\/ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca-ES"},{"@type":"Organization","@id":"https:\/\/raed.academy\/ca\/#organization","name":"Real Academia Europea de Doctores","url":"https:\/\/raed.academy\/ca\/","logo":{"@type":"ImageObject","inLanguage":"ca-ES","@id":"https:\/\/raed.academy\/ca\/#\/schema\/logo\/image\/","url":"https:\/\/raed.academy\/wp-content\/uploads\/2017\/01\/cropped-logo_raed.png","contentUrl":"https:\/\/raed.academy\/wp-content\/uploads\/2017\/01\/cropped-logo_raed.png","width":512,"height":512,"caption":"Real Academia Europea de Doctores"},"image":{"@id":"https:\/\/raed.academy\/ca\/#\/schema\/logo\/image\/"},"sameAs":["http:\/\/fb.me\/raed.academy","https:\/\/x.com\/raedacademy","https:\/\/www.instagram.com\/raed.academy\/","https:\/\/www.youtube.com\/channel\/UCUYQwW2KrdirNWihxMDObwg"]},{"@type":"Person","@id":"https:\/\/raed.academy\/ca\/#\/schema\/person\/5a755da80d1d979fd66ba745c8702927","name":"RAED","image":{"@type":"ImageObject","inLanguage":"ca-ES","@id":"https:\/\/secure.gravatar.com\/avatar\/19fdfdc0d67fb9c45714b703a2ac82251c4fcea3637f002ac3c9b74c0183583c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/19fdfdc0d67fb9c45714b703a2ac82251c4fcea3637f002ac3c9b74c0183583c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/19fdfdc0d67fb9c45714b703a2ac82251c4fcea3637f002ac3c9b74c0183583c?s=96&d=mm&r=g","caption":"RAED"}}]}},"_links":{"self":[{"href":"https:\/\/raed.academy\/ca\/wp-json\/wp\/v2\/posts\/121876","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/raed.academy\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/raed.academy\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/raed.academy\/ca\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/raed.academy\/ca\/wp-json\/wp\/v2\/comments?post=121876"}],"version-history":[{"count":0,"href":"https:\/\/raed.academy\/ca\/wp-json\/wp\/v2\/posts\/121876\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/raed.academy\/ca\/wp-json\/wp\/v2\/media\/122084"}],"wp:attachment":[{"href":"https:\/\/raed.academy\/ca\/wp-json\/wp\/v2\/media?parent=121876"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/raed.academy\/ca\/wp-json\/wp\/v2\/categories?post=121876"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/raed.academy\/ca\/wp-json\/wp\/v2\/tags?post=121876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}